1. Introduction {#sec1-ijms-16-22190}
===============

*Cichorium intybus* L. (also known as chicory) is a perennial herb from the *Asteraceae* family with both alimentary use and medicinal use. It is 40--100 cm in height, usually with bright blue flowers, rarely white or pink. It has been reported that fresh chicory typically contains 68% inulin, 14% sucrose, 5% cellulose, 6% protein, 4% ash, and 3% other compounds, while dried chicory contains approximately 98% inulin and 2% other compounds \[[@B1-ijms-16-22190]\]. *Cichorium intybus* L. is one of the most promising novel candidates among the carbohydrates with potential for both food and non-food utilization. With the function of diuresis, promoting digestion, curing jaundice, and benefiting kidney and liver function, according to the traditional herbalist doctor, it has been implemented in folk medicine from North Africa to South Asia for several centuries. It is worth noting that *Cichorium intybus* L. possesses a wide range of pharmacological properties according to the literature, including hepato-protective, anti-inflammatory, anti-malarial, anti-diabetic effects, *etc.* \[[@B2-ijms-16-22190],[@B3-ijms-16-22190],[@B4-ijms-16-22190],[@B5-ijms-16-22190],[@B6-ijms-16-22190]\]. In the present study, *Cichorium intybus* L. extract (CIE) exhibited a hepato-protective effect, as demonstrated by a significant decrease in aspartate aminotransferase (AST) and alanine aminotransferase (ALT) concentrations and the prevention of histopathological changes in the liver of mice with CCl~4~-induced hepatotoxicity. Moreover, CIE attenuated the reduction of glutathione (GSH) and superoxide dismutase (SOD), and decreased malondialdehyde (MDA) levels in mice with CCl~4~-induced hepatotoxicity \[[@B2-ijms-16-22190],[@B7-ijms-16-22190]\].

Although *Cichorium intybus* L. has distinct hepatic disease protection effects, its pharmacodynamic material basis and molecular mechanisms still need far more research. In this study, we analyzed the chemical composition of *Cichorium intybus* L., then certificated the structure of 10 compounds and determined their potential target proteins via SEA (similarity ensemble approach) docking. Based on the docking results, we chose two compounds (compounds **10** and **13**) and two of their key target proteins (Akt-1 and caspase-1) to conduct further study after applying gene ontology (GO) and KEGG orthology (KO) to find their functions and connections. Additionally, molecular modeling, molecular docking and MD simulation results proved good interaction between two small compounds and their targets. Finally, experimental validation, including western blot, was conducted to verify the active substance basis of the hepatic disease protection of *Cichorium intybus* L. *In silico* analysis and experimental validation together demonstrated that selected compound **13** in *Cichorium intybus* L. targeted RAC-α serine/threonine-protein kinase (Akt-1) and caspase-1 in hepatocytes, while compound 10 targeted Akt-1. What has been discussed above indicates that these two compounds in *Cichorium intybus* L. may ameliorate liver injury.

2. Results {#sec2-ijms-16-22190}
==========

2.1. The Effect of Cichorium intybus L. on Liver Injury Protection {#sec2dot1-ijms-16-22190}
------------------------------------------------------------------

Compared with the injury model group, serum ALT level and AST level in the middle-dose group (6.0 g/kg chicory) were significantly reduced, while there were no obvious changes in the low-dose group (2.0 g/kg chicory) and the high-dose group (18.0 g/kg chicory) ([Figure 1](#ijms-16-22190-f001){ref-type="fig"}A,B).

Liver tissue GSH level ([Figure 1](#ijms-16-22190-f001){ref-type="fig"}C) was significantly reduced and MDA level ([Figure 1](#ijms-16-22190-f001){ref-type="fig"}D) went up in the middle-dose group, while there were no obvious changes in low- and high-dose groups, compared with the model group.

![(**A**) Serum ALT (alanine aminotransferase) level in mice; (**B**) serum AST (aspartate aminotransferase) level in mice; (**C**) liver tissue GSH (glutathione) level in mice; and (**D**) liver tissue MDA (malondialdehyde) level in mice. **\***, *p* \< 0.05; **\*\***, *p* \< 0.01.](ijms-16-22190-g001){#ijms-16-22190-f001}

[Figure 2](#ijms-16-22190-f002){ref-type="fig"}A--F shows the liver tissue histopathological observation results of all six groups. It can been seen from the figure that liver cells were arranged radially around the central veios in the normal control, while acute pathological changes occurred in liver injury model group, including centrilobular hepatic necrosis, the deformation of macrophage and ballooning, and a large number of inflammatory cells infiltration. The silibinin group and middle-dose group can ameliorate the injury apparently.

The result of ROS (reactive oxygen species) detection further demonstrated the protective activity of *Cichorium intybus* L. Compared with the normal group, many more cells from the model group died. The middle-dose of *Cichorium intybus* L. could obviously protect hepatocytes from apoptosis, the same effect as Silibinin, while the low-dose group or high-dose group did not show the same effect ([Figure 2](#ijms-16-22190-f002){ref-type="fig"}B).

![(**A**) Liver tissue histopathological observation results, (**a**) normal control; (**b**) liver injury model; (**c**) positive drug silibinin control (200 mg/mL); (**d**) low-dose drug group (2.0 g/kg chicory); (**e**) middle-dose group (6.0 g/kg chicory); and (**f**) high-dose group (18.0 g/kg chicory); and scale bar = 100 μm; (**B**) ROS detection result, (**a**) normal control; (**b**) liver injury model; (**c**) positive drug silibinin control (200 mg/mL); (**d**) low-dose drug group (2.0 g/kg chicory); (**e**) middle-dose group (6.0 g/kg chicory); (**f**) high-dose group (18.0 g/kg chicory); and (**g**) quantitative analysis of ROS detection. FSC-H and SSC-H represent cell numbers and fluorescence intensity, respectively.](ijms-16-22190-g002){#ijms-16-22190-f002}

2.2. Small Molecule Compounds and Target Proteins {#sec2dot2-ijms-16-22190}
-------------------------------------------------

We identified structures of 10 small molecule compounds in *Cichorium intybus* L., which are shown in [Table 1](#ijms-16-22190-t001){ref-type="table"}. Among them, compounds **2** and **5** were new compounds that had not been reported; compound **6** was isolated from the genus for the first time; and compound **10** was isolated from this plant for the first time. We then found the target proteins of eight of them ([Table 2](#ijms-16-22190-t002){ref-type="table"}). After we found the functions of these proteins, we chose compound **10** (methyl 4-hydroxyphenylacetate) and compound **13** (4-hydroxylphenylacetic acid) and their target proteins to conduct our further study.

ijms-16-22190-t001_Table 1

###### 

The structures of compounds in *Cichorium intybus* L.

  Number   Name                                         Structure                     Identification Means
  -------- -------------------------------------------- ----------------------------- ---------------------------------------------------------------------
  **2**    Intyboate B                                  ![](ijms-16-22190-i001.jpg)   ^13^C-NMR; ^1^H-NMR; HMBC; HSQC; NOESY; m.p.; UV; CD; HR-ESI-TOF-MS
  **5**    3a*R*-santamarine                            ![](ijms-16-22190-i002.jpg)   ^13^C-NMR; ^1^H-NMR; HMBC; HMQC; NOSEY; m.p.; UV; CD; HR-ESI-TOF-MS
  **6**    Aurantiamide acetate                         ![](ijms-16-22190-i003.jpg)   ^13^C-NMR; ^1^H-NMR; HMBC; HMQC; m.p.; UV; CD; HR-ESI-TOF-MS
  **7**    Luteolin-7-*O*-β-[d]{.smallcaps}-glucoside   ![](ijms-16-22190-i004.jpg)   ^13^C-NMR; ^1^H-NMR; m.p.; HR-ESI-TOF-MS
  **8**    Luteolin                                     ![](ijms-16-22190-i005.jpg)   ^13^C-NMR; ^1^H-NMR; HR-ESI-TOF-MS
  **9**    Caffeic acid                                 ![](ijms-16-22190-i006.jpg)   ^13^C-NMR; ^1^H-NMR; HR-ESI-TOF-MS
  **10**   Methyl 4-hydroxyphenylacetate                ![](ijms-16-22190-i007.jpg)   ^13^C-NMR; ^1^H-NMR; HMBC; HMQC; HR-ESI-TOF-MS
  **11**   β-sitosterol                                 ![](ijms-16-22190-i008.jpg)   TLC
  **12**   Daucosterol                                  ![](ijms-16-22190-i009.jpg)   TLC
  **13**   4-Hydroxylphenylacetic acid                  ![](ijms-16-22190-i010.jpg)   HR-ESI-TOF-MS

HMBC, heteronuclear multiple-bond correlation; HSQC, heteronuclear singular quantum correlation; NOESY, nuclear overhauser effect spectroscopy; m.p., melting point; UV, ultraviolet spectrum; CD, circular dichroism spectrum; HR-ESI-TOF-MS, high-resolusion electrospray-ionization time-of-flight mass spectrometry; TLC, thin-layer chromatography.

ijms-16-22190-t002_Table 2

###### 

Target proteins of small compounds in *Cichorium intybus* L.

  Number              Name                                         ZINC           Target              UniProtKB AC   Recommended Name
  ------------------- -------------------------------------------- -------------- ------------------- -------------- -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  **1**               Intyboate A                                  None           ACE_MOUSE_100       P09470         Angiotensin-converting enzyme
  **2**               Intyboate B                                  None           ACE_MOUSE_100       P09470         Angiotensin-converting enzyme
  **5**               3a*R*-santamarine                            ZINC05663288   None                None           None
  **7**               Luteolin-7-*O*-â-[d]{.smallcaps}-glucoside   ZINC03947434   TOP1_MOUSE_10000    Q04750         DNA topoisomerase 1; Interleukin-5; Aldo-ketoreductase family 1 member C21; Multidrug resistance protein 3; γ-Aminobutyric acid receptor subunit α-1
  IL5_MOUSE_10000     P04401                                                                                         
  AK1CL_MOUSE_10000   Q91WR5                                                                                         
  MDR3_MOUSE_10000    P21440                                                                                         
  GBRA1_MOUSE_10      P62812                                                                                         
  **8**               Luteolin                                     ZINC18185774   AK1CL_MOUSE_10000   Q91WR5         Aldo-ketoreductase family 1 member C21; Multidrug resistance protein 3; Tyrosinase; γ-Aminobutyric acid receptor subunit α-1; Interleukin-5; Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit α isoform; Dual specificity protein phosphatase 1; Solute carrier family 22 member 6
  MDR3_MOUSE_100      P21440                                                                                         
  TYRO_MOUSE_10000    P11344                                                                                         
  GBRA1_MOUSE_1000    P62812                                                                                         
  IL5_MOUSE_10000     P04401                                                                                         
  PK3CA_MOUSE_10000   P42337                                                                                         
  DUS1_MOUSE_10000    P28563                                                                                         
  S22A6_MOUSE_10000   Q8VC69                                                                                         
  **9**               Caffeic acid                                 ZINC00058172   MDR2_MOUSE_10000    None           Multidrug resistance protein 1B; Multidrug resistance protein 3; Transcription factor HES-1; Dual specificity tyrosine-phosphorylation-regulated kinase 1A; Epidermal growth factor receptor; Carbonic anhydrase 15; Retinoic acid receptor RXR-α
  MDR1_MOUSE_10000    P06795                                                                                         
  MDR3_MOUSE_10000    P21440                                                                                         
  HES1_MOUSE_10000    P35428                                                                                         
  DYR1A_MOUSE_10000   Q61214                                                                                         
  EGFR_MOUSE_10000    Q01279                                                                                         
  CAH15_MOUSE_10000   Q99N23                                                                                         
  RXRA_MOUSE_1000     P28700                                                                                         
  **10**              Methyl 4-hydroxyphenylacetate                ZINC00395674   ACE_MOUSE_1000      P09470         Angiotensin-converting enzyme; Solute carrier family 22 member 20; Solute carrier family 22 member 6; Platelet-derived growth factor receptor α (PDGFRα); Carbonic anhydrase 15; Mu-type opioid receptor; Bifunctional epoxide hydrolase 2; RAC-α serine/threonine-protein kinase (Akt-1); M-phase inducer phosphatase 2
  S22AK_MOUSE_10000   Q80UJ1                                                                                         
  S22A6_MOUSE_10000   Q8VC69                                                                                         
  PGFRA_MOUSE_1000    P26618                                                                                         
  CAH15_MOUSE_10000   Q99N23                                                                                         
  OPRM_MOUSE_10       P42866                                                                                         
  HYES_MOUSE_10000    P34914                                                                                         
  AKT1_MOUSE_10000    P31750                                                                                         
  MPIP2_MOUSE_10000   P30306                                                                                         
  **13**              4-Hydroxylphenylacetic acid                  ZINC00213065   ACE_MOUSE_1000      P09470         Angiotensin-converting enzyme; Solute carrier family 22 member 6; Caspase-1; Glycine receptor subunit α-4; Solute carrier family 22 member 20; RAC-α serine/threonine-protein kinase (Akt-1); Prostaglandin G/H synthase 2; Carbonic anhydrase 15; Hydroxycarboxylic acid receptor 2; Platelet-derived growth factor receptor α(PDGFRα)
  S22A6_MOUSE_10000   Q8VC69                                                                                         
  CASP1_MOUSE_10      P29452                                                                                         
  GLRA4_MOUSE_10000   Q61603                                                                                         
  S22AK_MOUSE_10000   Q80UJ1                                                                                         
  AKT1_MOUSE_10000    P31750                                                                                         
  MDR2_MOUSE_10000    None                                                                                           
  PGH2_MOUSE_1000     Q05769                                                                                         
  CAH15_MOUSE_10000   Q99N23                                                                                         
  HCAR2_MOUSE_10000   Q9EP66                                                                                         
  PGFRA_MOUSE_1000    P26618                                                                                         

UniProtKB AC means UniProt Knowledgebase number.

2.3. Molecular Modeling, Molecular Docking and MD Simulation {#sec2dot3-ijms-16-22190}
------------------------------------------------------------

From small molecule compounds targeting caspase-1 and Akt-1, compound **13** was selected for virtual screening with molecular modeling, molecular docking and MD simulations, for its effect of hepatic fibrosis. Compound **10** was also selected for targeting Akt-1. Results of molecular docking showed that they are both top-scored for the target proteins, means that they indeed can interact with the targets ([Figure 3](#ijms-16-22190-f003){ref-type="fig"}). MD simulations of the compounds **10** and **13** and their targets were carried out, to further confirm precise binding mechanisms and interaction stability. And the results indicated the stabilities of the dynamics equilibriums for both of them are reliable, and thus provide a reliable basis for further analysis.

2.4. The Effect of Compound **10** and Compound **13** on Disease Protection in Mice Hepatocytes {#sec2dot4-ijms-16-22190}
------------------------------------------------------------------------------------------------

Both Akt-1 and caspase-1 were highly expressed when the liver was injured. The expression level of caspase-1 and Akt-1 decreased in the mixture group and compound **13** group compared to the liver injury model group, indicating a hepatic protective effect ([Figure 4](#ijms-16-22190-f004){ref-type="fig"}). From what was discussed above, it can be inferred that compound **13** in *Cichorium intybus* L. reduced the expression level of Akt-1 and caspase-1, thus ameliorated the liver injury to some degree.

![(**A**) The binding mode of compound **13** in caspase-1; and (**B**) the binding mode of compounds **10** and **13** in Akt-1.](ijms-16-22190-g003){#ijms-16-22190-f003}

![Expression level of caspase-1 and Akt-1 in mice.](ijms-16-22190-g004){#ijms-16-22190-f004}

3. Discussion {#sec3-ijms-16-22190}
=============

In this study, we demonstrated the hepatoprotective effect of *Cichorium intybus* L*.* on mouse model. Furthermore, it can be inferred that *Cichorium intybus* L*.* will have great value in hepatic disease protection, whether for alimentary or medicinal use. Since *Cichorium intybus* L. has complex chemical components, to identify the small molecule compounds and their biological targets has become significant. Therefore, we separated and identified 10 of them. Among them, compounds **2** and **5** were new compounds that had not been reported; compound **6** was isolated from the genus for the first time; and compound **10** was isolated from this plant for the first time. These new compounds may inspire people investigating more about the therapeutic potential of *Cichorium intybus* L*.*, apart from the effective components like Intyboate B that we have already known for its therapeutic effect on hypertension, heart failure, *etc.*

Among the targets of the two selected compounds, Akt-1 and caspase-1 are extremely significant. Akt-1 can prevent apoptosis and high expression level of it may be related to tumorigenesis \[[@B8-ijms-16-22190]\]. Caspase-1 is involved in apoptosis mediated by death receptor \[[@B9-ijms-16-22190],[@B10-ijms-16-22190]\]. The hepatic protective effect of compounds **10** and **13** may be reflected from two aspects: on the one hand, they can down regulate abnormally high expression of Akt-1 and thus prevent the occurrence of tumors; on the other hand, compound **13** also inhibits the expression of caspase-1 and thereby reduces the degree of liver damage via preventing apoptosis. The results of western blot have strongly proved our hypothesis. In addition, since Akt-1 pathway has an extensive biological effect, especially in preventing apoptosis, regulating metabolism and resulting in cytoskeleton reorganization, we can speculate that studies on compounds **10** and **13** are of great significance in the treatment of several diseases including diabetes mellitus.

By applying *in silico* analysis and experimental validation, our study has proven the hepato-protective effect of compounds **10** and **13** in *Cichorium intybus* L. and disclosed its possible molecular mechanisms, which may shed light on designing the drugs aimed at acute liver injury.

4. Experimental Section {#sec4-ijms-16-22190}
=======================

4.1. Experimental Animals and Design {#sec4dot1-ijms-16-22190}
------------------------------------

Experiments were conducted on male Kunming mice (Specific pathogen free (SPF) grade), which weighed 20 ± 2 g, and were purchased from the Experimental Animal Center of Xinjiang Medical University (Xinjiang, China), license number: SYXK (Xin) 2003-0001. After 1 week of feeding in a constant temperature of 21--24 °C and 45%--50% relative humidity, the mice were used for experiments. The feedstuffs were provided by the Animal Experimental Center of Shihezi University. Mice were randomly divided into 6 groups of 12 mice each, including the normal control, liver injury model, positive drug silibinin control (200 mg/mL), low-dose drug group (2.0 g/kg chicory), middle-dose group (6.0 g/kg chicory) and high-dose group (18.0 g/kg chicory). The normal group and model group were fed with physiological saline for 7 days, while other groups were fed with the corresponding agents. One hour after the last drug administration, all groups, except the normal control, received a peritoneal injection of 10 mL/kg of 0.2% rapeseed oil solution of CCL~4~. All groups were allowed free access to pure water but no access to food. After 20 h, blood and liver tissue samples were harvested for further examination.

4.2. Measurement of Markers of Liver Function and Enzyme Activity {#sec4dot2-ijms-16-22190}
-----------------------------------------------------------------

The blood was centrifuged at 3000 r/min at 4 °C for 10 min to separate the serum. Markers of liver function, including aspartate transaminase (AST) and alanine transaminase (ALT), were measured with a UV spectrophotometer (Shimadzu UV-2401, Shimadzu, Kyoto, Japan). The liver tissue was prepared as a 10% homogenate (*w*/*v*). MDA was measured by using a MDA kit, with a UV spectrophotometer (Shimadzu UV-2401) at 532 nm. GSH was measured by using a GSH kit, with a UV spectrophotometer (Shimadzu UV-2401) at 420 nm.

4.3. Histopathological Observations in the Liver {#sec4dot3-ijms-16-22190}
------------------------------------------------

Mouse liver tissue was fixed with 10% formalin for 24 h, dehydrated with a sequence of ethanol solutions, and embedded in paraffin. Serial sections were cut at a 5 μm thickness and stained with hematoxylin-eosin (HE) and masson tri-chrome. Stained tissue sections were assessed for the detection of changes in the magnitude of liver injury using a photomicroscope.

4.4. Detection of ROS and Immunostaining {#sec4dot4-ijms-16-22190}
----------------------------------------

Intracellular ROS levels were measured using dichloro-dihydro-fluorescein diacetate (DCFH-DA). For flow cytometric analyses, cells were exposed to 10 μM DCFH-DA (Invitrogen, San Diego, CA, USA) for 5 min. The cells were then analyzed using a FACSCalibur flow cytometer (BD Biosciences, San Jose, CA, USA) using the FL-1 channel (515--545 nm). The mean fluorescence intensity (MFI) was analyzed using CellQuest Pro 4.0.2 software (BD Biosciences, San Jose, CA, USA), and quantification was performed using WinMDI 2.8 software (The Scripps Institute, La Jolla, CA, USA). Small cellular debris was excluded by gating on a forward scatter plot \[[@B11-ijms-16-22190],[@B12-ijms-16-22190],[@B13-ijms-16-22190],[@B14-ijms-16-22190],[@B15-ijms-16-22190]\].

4.5. Isolation and Identification of Main Components in Cichorium intybus L. {#sec4dot5-ijms-16-22190}
----------------------------------------------------------------------------

We isolated 14 compounds and identified 10 of the structures by applying Sephadex LH-20 (General Electric, Fairfield, CA, USA), Open ODS (Octadecylsilyl, Shimadzu, Kyoto, Japan), UPLC-TOF-MS (ultra performance liquid chromatography/time of flight mass spectrometry, Waters, Milford, MA, USA), *etc.* In brief, herbs of *Cichorium intybus* L. (10.0 kg) were extracted with EtOH-H~2~O (95:5, *v*/*v*) three times under conditions of reflux for 3 h each time. The combined EtOH extracts were concentrated, suspended in H~2~O, and then partitioned with CHCl~3~ and EtOAc, to yield CHCl~3~-soluble fraction (46.0 g) and EtOAc-soluble fraction (24.0 g). An aliquot of the CHCl~3~-soluble fraction (40.0 g) was subjected to silica gel CC with a gradient of petroleum ether (PE)/EtOAc to afford fourteen fractions A--N (100:0--100:100). Fraction C (PE-EtOAc, 100:1) (0.0748 g) was applied to silica gel CC eluted with petroleum ether (PE)/EtOAc (100:2) to produce compound **13** (30.0 mg). An aliquot of the CHCl~3~-soluble fraction (20.0 g) was subjected to silica gel CC with a gradient of CHCl~3~/MeOH to afford eight fractions A--H (100:0--100:10). Fraction F (CHCl~3~/MeOH, 100:6) (0.5 g) was applied to silica gel CC and Sephadex LH-20 (General Electric, Fairfield, CA, USA) successively, then separated via HPLC (Shimadzu, Kyoto, Japan), with MeOH-H~2~O (45:55, *v*/*v*) as mobile phase, to produce compound **10** (12.0 mg). The structures of compounds **10** and **13** were identified by comparison of their spectroscopic data with those reported in the literature \[[@B16-ijms-16-22190],[@B17-ijms-16-22190],[@B18-ijms-16-22190],[@B19-ijms-16-22190],[@B20-ijms-16-22190]\]. The relevant chromatograms and mass spectra data of the active compounds are as follows.

Compound **10**: colorless acicular crystal (MeOH); HR-ESI-TOF-MS 167.0705 \[M + H\]^+^ (calculated 167.0708, C~9~H~11~O~3~); ^1^H-NMR (CD~3~OD, 600 MHz) δ: 7.07 (2H, d, *J* = 8.4 Hz, H-2, H-6), 6.72 (2H, d, *J* = 8.4 Hz, H-3, H-5), 3.66 (3H, s, --OCH~3~), 3.52 (2H, s, H-7); ^13^C-NMR (CD~3~OD, 150 MHz) δ: 173.1 (C-8), 156.2 (C-4), 129.9 (C-2, C-6), 124.5 (C-1), 114.9 (C-3, C-5), 50.9 (C-1ʹ), 39.5 (C-7).

Compound **13**: colorless acicular crystal (MeOH); HR-ESI-TOF-MS 153.0549 \[M + H\]^+^ (calculated 153.0551, C~8~H~9~O~3~); ^1^H-NMR(CD~3~OD, 600 MHz) δ: 7.00 (2H, d, *J* = 8.4 Hz, H-2, H-6), 6.67 (2H, d, *J* = 8.4 Hz, H-3, H-5), 3.46 (2H, s, H-7), 9.27 (1H, br s, OH); ^13^C-NMR (CD~3~OD, 150 MHz) δ: 176.1 (C-8), 157.4 (C-4), 131.3 (C-2, C-6), 126.8 (C-1), 116.2 (C-3, C-5), 41.1 (C-7).

4.6. Predictive Targets of Small Molecule Compounds {#sec4dot6-ijms-16-22190}
---------------------------------------------------

Target proteins of the small molecule compounds were obtained from the similarity ensemble approach (SEA) (<http://sea.bkslab.org/>) \[[@B21-ijms-16-22190]\]. An assistant tool for searching data from SEA dock was developed to simplify this process. The assistant tool can view the source code of the result page and test if the content matches the pattern that we set. If it does match, the program will copy it into a buffer and dump it into a file. Then the functions of target proteins and connections between them were obtained by applying Gene Ontology (GO) (<http://www.geneontology.org>) and KEGG Orthology (KO) (<http://www.genome.jp/kegg/ko.html>) \[[@B22-ijms-16-22190],[@B23-ijms-16-22190],[@B24-ijms-16-22190]\]. Furthermore, we selected target proteins involved in disease pathogenesis in liver.

4.7. Molecular Modeling and Molecular Docking {#sec4dot7-ijms-16-22190}
---------------------------------------------

We selected 2 effective small molecule compounds and 2 proteins as receptors. Before the docking, we downloaded initial three-dimensional geometric co-ordinates of the X-ray crystal structures of compounds and proteins from the Protein Data Bank (PDB) (<http://www.pdb.org/pdb/home/home.do>). Molecular docking was performed using the UCSF DOCK6.5 program (University of California, San Francisco, CA, USA), which utilized DOCK algorithm to address rigid body docking by superimposing the ligand on to a negative image of the binding pocket \[[@B25-ijms-16-22190],[@B26-ijms-16-22190],[@B27-ijms-16-22190]\].

4.8. MD Simulations of Complexes {#sec4dot8-ijms-16-22190}
--------------------------------

Refinements of 3D structures of complexes were done using 10 ns molecular dynamic (MD) simulations. MD simulation of the complex was carried out with the GROMACS 4.5.4 (KTH Royal Institute of Technology, Stockholm, Sweden) \[[@B28-ijms-16-22190]\] package using the GROMOS96 43a1 force field \[[@B29-ijms-16-22190]\]. The lowest binding energy (most negative) docking conformation generated by CDOCKER module embedded in the Accelrys Discovery Studio 3.5 (Accelrys, San Diego, CA, USA) was taken as initial conformation for MD simulation. The topology parameters of proteins were created using the Gromacs program. The topology parameters of ligands were built by the Dundee PRODRG server (University of Dundee, Dundee, UK). The complex was immersed in a cubic box of simple point charge (SPC) water molecules. Eight and eleven sodium counter-ions were added by replacing water molecules to ensure the overall charge neutrality of the receptors simulated system, respectively. To release conflicting contacts, energy minimization was performed using the steepest descent method of 5000 steps followed by the conjugate gradient method for 5000 steps. MD simulation studies consist of equilibration and production phases. To equilibrate the system, the solute was subjected to the position-restrained dynamics simulation (NVT (constant number (N), volume (V), and temperature (T)) and NPT (constant number (N), pressure (P), and temperature (T)) at 300 K for 300 ps. Finally, the full system was subjected to MD production run at 300 K temperature and 1 bar pressure for 5000 ps. For analysis, the atom coordinates were recorded at every 0.5 ps during the MD simulation.

4.9. Western Blot Analysis {#sec4dot9-ijms-16-22190}
--------------------------

The expression levels of the selected target proteins (Akt-1 and caspase-1) in liver tissues were measured by applying western blot. Liver tissues were lysed in a buffer containing 1% Triton X-100, 50 mM Tris (pH 7.5), 10 mM EDTA, 0.02% NaN~3~, and a protease inhibitor cocktail (Roche Boehringer Mannheim Diagnostics, Mannheim, Germany). Following one freeze--thaw cycle, the cell lysates were centrifuged at 10,000× *g* at 4 °C for 20 min and boiled in sample buffer for 5 min. The proteins were then subjected to SDS--PAGE (sodium dodecyl sulfate polyacrylamide gel electrophoresis) and transferred to a PVDF (polyvinylidene fluoride) membrane (Millipore, Billerica, MA, USA) using a semi-dry electroblotting system. After blocking with 5% skim milk in PBS, the membranes were incubated with primary antibodies (1:1000 dilution) at 4 °C overnight. The membranes were then washed with PBS containing 0.05% Tween 20 and incubated with horseradish peroxidase (HRP)-conjugated secondary antibodies (1:5000 dilution) at room temperature for 1 h. After washing, the membranes were soaked in ECL solution (PerkinElmer Life Sciences Inc., Boston, MA, USA) for 1 min, according to the manufacturer's instructions, and exposed to film (BioMax; Eastman Kodak, Rochester, NY, USA). Other materials used for protein analyses were purchased from Sigma-Aldrich (Sigma-Aldrich, St. Louis, MO, USA) \[[@B30-ijms-16-22190],[@B31-ijms-16-22190],[@B32-ijms-16-22190]\].

4.10. Statistical Analysis {#sec4dot10-ijms-16-22190}
--------------------------

All the presented data and results were confirmed in at least three independent experiments. The data are expressed as means ± S.D. Statistical comparisons were made by One-way ANOVA and Student's *t*-test. *p* \< 0.05 was considered statistically significant.

5. Conclusions {#sec5-ijms-16-22190}
==============

This study demonstrates the hepatic protective effect of *Cichorium intybus* L. and active compounds in *Cichorium intybus* L. The active compounds ameliorate liver injury by acting on Akt-1 and caspase-1, which are related to apoptosis or autophagy. In summary, our results may shed light on the complex molecular mechanisms of *Cichorium intybus* L. acting on hepatocytes and ameliorating liver injury.
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CIE, *Cichorium intybus* L. extract; AST, aspartate aminotransferase; ALT, alanine aminotransferase; GSH, glutathione; SOD, superoxide dismutase; MDA, malondialdehyde; ROS, reactive oxygen species; Akt-1, RAC-α serine/threonine-protein kinase; CCL~4~, carbon tetrachloride.
